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Overview
An opportunity arose in April 2007 for a secondment into the 
clinical PET/CT fi eld. It came at a transitional period for PET, because 
the Government had announced plans for the increased provision 
of PET scans through managed service agreements with medical 
imaging companies, such as Alliance Medical Ltd (AML) – the result 
of an initial consultation document undertaken by the Department 
of Health in 2005, assessing the overall delivery of PET services in 
England, compared to other countries1. Although I was a practicing 
diagnostic radiographer and nuclear medicine practitioner, this was 
a journey through uncharted waters, in terms of the patient groups 
encountered, handling a Beta emitting radioisotope, and appreciating 
the various facets of a modern PET/CT practice. A constructivist model 
of emotional learning2 was adopted throughout the clinical placement 
and, although the prospect of working alongside clinical practitioners 
was an exciting thought, it was also very daunting. 
The training received before and during the clinical placement 
was essential to the provision of a safe and effective PET/CT service. 
This included a series of competency based practical assessments, 
probationary reports, and undertaking a College of Radiographers 
approved injection course. Being able to transfer academic 
knowledge and understanding of PET/CT into the clinical fi eld 
required personal adjustment and cognitive skill development. 
It soon became apparent that the use of PET/CT within practice was 
evolving. The referral of patients for scans now covers a wide range 
of clinical pathologies, including the most current cancers, such as 
lung, colon, lymphoma and melanoma. In line with diagnostic and 
treatment pathways identifi ed by the National Institute for Clinical 
Excellence (NICE), PET/CT was being utilised as a diagnostic staging 
and monitoring tool for patients. In a number of cases, its use was 
impacting on the overall staging of patients and providing crucial 
information for surgeons and other healthcare professionals at multi-
disciplinary team (MDT) meetings.  
Physical working environment
PET/CT practitioners arrive at mobile clinical sites around 7 to 7.30am to 
prepare for the working day and undertake the various quality control 
checks – because the mobile units are transported around the country, 
it is crucial to check for any issues which could have a detrimental 
effect on the overall quality of the patient scans. This included 
ensuring that the crystals are fully operational (ie, coincidence mean, 
gain values and singles test) and that there are no alignment issues. 
Being able to recognise and problem-solve hardware and software 
faults requires knowledge, understanding, good training and the 
employment of transferrable skills. A good working relationship with 
the trailer drivers and equipment engineers also helped!
In addition, the paperwork is collected from site, referral forms 
are checked, and a signature from the clinician who holds the 
Administration of Radioactive Substances Act Committee (ARSAC)3
licence is ensured. This is crucial, because the introduction of a 
radioactive substance into a patient’s bloodstream induces a radiation 
risk. Obviously, the risk benefi t analysis is carried out (Ionising 
Radiation (Medical Exposure) Regulations 2000) for each patient to 
ensure the PET/CT examination provides benefi cial results.
The initial reaction to being on board a mobile PET/CT scanner is 
one of space, or lack of it to be precise – it is unfortunately small 
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(fi gure 1) and weighs approximately 46 tons due to the lead shielding 
required. The ‘pop out’ sections (fi gure 2) enable additional space for 
operators, but this is limited compared to a static PET/CT environment. 
Practical working skills had to be developed in terms of distance 
and shielding, something that radiographers and nuclear medicine 
practitioners are taught very early on in their training. Issues related to 
potential ‘crossfi re’ from having radioactive patients either side of the 
control area means that consideration is needed for patients’ overall 
safety on entering and exiting the environment. Standing at the side of 
the scanner whilst the table is moving up and down generally protects 
the operator, and the composite material is Kevlar which offers some 
form of practical radiation protection. 
Patient experience
It was important to appreciate the patient ‘journey’ before, during and 
after a PET/CT scan. Patients demonstrate various emotional states after 
receiving potentially life-changing information within the oncology 
setting. Some were informed of their clinical diagnosis literally days 
before their scan and I hadn’t previously encountered such intensity 
of feelings. The scans were also used to evaluate treatment, post-
chemotherapy, and I was fortunate enough to witness numerous cases 
where it had made a substantial difference to the overall management 
of patients. It was at these moments that the true potential and 
diagnostic value of PET/CT became clear and felt more personal than 
reading about sensitivity and specifi city values in a journal article!  
Patient preparation is paramount for any examination or treatment 
procedure. In addition to verbal discussions, patients also receive 
a booklet relaying information about their scan, preparation 
requirements, aftercare considerations and how the procedure may 
be utilised in their particular case. However, it became apparent 
early on that some patients receive very little information prior to 
their scan – mainly due to the fact that some referrers (eg, consultant 
oncologists) request PET/CT scans within a very short time frame. The 
reason is two fold: fi rstly, to be in line with the Department of Health’s 
Cancer Plan4 initiative that waiting times of patients must be minimised 
and, secondly, the effi cacy of PET/CT defi nes the individual treatment 
a patient receives. Also, the amount of patients who did not read the 
information or chose to ignore it was concerning at times.
There is a considerable amount of patient preparation, more than 
Figure 1: A mobile PET/CT scanner environment. Note the close proximity 
of the trailer walls, which are lead-lined to minimise radiation dose to the 
outside public and workers.
Figure 2: External view of a mobile PET/CT unit. The oval shows the 
scanner environment; the square, the control console; and the triangle, 
the patient injection/uptake area.
Figure 3: An anxious patient who demonstrated symmetrical ‘brown fat’ 
uptake within the neck.
I had considered from initial theoretical experience. Although the 
standard preparation is relatively straightforward (see appendix on 
http://synergy.sor.org/january2009) and generally includes fasting 
for a minimum of six hours prior to a scan, there appears to be 
potential issues for patients who are either type I or type II diabetic, 
chemotherapy patients, and patients who have undergone some 
form of lymphatic drainage (eg, breast cancer). Individual alterations 
are also needed depending on the specifi c requirements of the 
examination or the patient. For example, patients should avoid any 
strenuous exercise before the scan – recent muscle usage and/or 
patient tension/anxiety may lead to the uptake of FDG-18 post-
injection, known as ‘brown fat’ uptake (fi gure 3). 
Large patients sometimes faced diffi culties in being comfortable 
within the actual PET/CT scanner (fi gure 1). Although the imaging 
bore is relatively generous, the limited attenuation correction fi eld of 
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view (FOV) (50 cms) within the GE Discovery PET/CT scanner resulted 
in some larger patients not having a full attenuation correction FOV 
algorithm applied to the raw PET data. This was inevitable in larger 
patients and was subsequently documented within the specifi c 
patient’s paperwork.
Similar to other nuclear medicine procedures, patients and their 
carers (if required) are informed of the radioactive nature of the PET 
procedure, via the patient information booklet and during the actual 
imaging procedure. Due to the relatively higher linear energy transfer 
(LET) of beta particles, compared with gamma and x-ray energy 
sources, the importance of time, distance and shielding became 
apparent very early on. For example, judging some patients’ ability 
to help themselves off the scanner took some practice, rather than 
assistance being given and personal dose being increased.  
FDG-18 production, delivery and management
The FDG-18 radioisotope is produced within a cyclotron unit, a 
specialist machine where the bombardment of a target element (eg, 
oxygen) by particles occurs at a very high speed. This ultimately 
creates an unstable element (eg, Fluorine-18), which is attached to 
a glucose solution, to create FDG-18. This solution has a very short 
physical half-life (110 minutes) and needs to be transported to both 
mobile and static PET/CT facilities very quickly. 
Licenced road vehicles transport the FDG in specialised containers 
to clinical sites and the amount of paperwork is extensive in terms 
of ensuring the hand-over of this licenced medical product. Strict 
regulations, such as the Radioactive Substances Act5 have to be 
adhered to when transporting any radioactive material. Each container 
holds a single vial of FDG-18 radioisotope solution (fi gures 4 and 5a & 5b).
Taking into account the short half-life of FDG-18 is vital: each 
patient’s arrival would be built into the overall management of the 
service. Sometimes an accident on the motorway would result in 
late delivery, causing concern in relation to the provision of suffi cient 
FDG-18 activity and booked patients. A number of incidents involving 
the FDG-18 solution failing the strict quality control procedures also 
occurred. It was sometimes diffi cult to re-organise patients, especially 
if some of them had not eaten for a considerable amount of time, or if 
they were diabetic. 
It was apparent that effective communication and problem solving 
skills were two of the fundamental attributes of a PET/CT practitioner. 
All healthcare professionals utilise these skills, but it was clear 
that, in order to manage a PET/CT service, particularly in a mobile 
environment, practitioners had to be able to foresee problems and 
effectively manage them. Support was available through various facets 
and managerial roles, but the dedication and drive to ensure minimal 
disruption to the provision of the PET/CT service by the practitioners 
I worked alongside was clear. It was as upsetting for them as for 
the patients when a scan had to be cancelled for reasons totally 
beyond their control. I can’t recall ever seeing such dedication and 
commitment from a workforce and the feeling of complete empathy 
for the patients.
Injecting skills and protocols
FDG-18 controlled the working day. Without this radiopharmaceutical 
agent, it wasn’t possible to achieve anything. Every PET/CT practitioner 
has a level of respect for the solution, in terms of its cost, potential 
diagnostic properties and biological damage to patients if injected 
incorrectly, but gaining confi dence in its administration was, 
personally, a relatively slow process. 
It is routine protocol for the areas in the south of England to utilise 
Figure 5a: Inside 
view of the 
specialised transport 
container. The 
FDG-18 vial sites 
inside the middle of 
the cylindrical lead 
container and the 
whole packaging 
is designed to 
withstand a high 
impact velocity 
accident. 
Figure 4: Specialised 
containers that 
house a lead-
lined case.
Figure 5b: Housing ‘pig’ of 
the FDG-18 vial. Note the 
thickness of the ‘pig’ and 
the lead glass screen.
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blue venfl ons for the administration of FDG-18. Working closely with 
clinical colleagues and appreciating the importance of good venous 
access is probably one of the most fundamental factors of being a 
PET/CT practitioner. This was probably over-stressed frequently by 
colleagues, but with valid reason. 
Sometimes the venous access for patients who have undergone 
chemotherapy treatment is poor and the team approach to injecting 
patients with diffi cult veins demonstrated the true meaning of 
teamwork, professional trust and commitment to obtaining quality 
diagnostic results. A number of patients have to be injected in their 
feet, because lymph node clearance precludes venous access in the 
affected side of a patient with breast cancer. This is due to the poor 
clearance of the FDG-18 radioactive tracer and inaccessible veins 
in the opposite arm of the patient. Sometimes, patients who had 
experienced a large number of chemotherapy cycles would present 
with an expression of worry and stress, mainly because venous access 
would be a problem. However, the clinical composure, compassion 
and concern for patient safety was always demonstrated by my 
colleagues, sometimes under immense pressure to administer the 
FDG-18 solution within a certain time limit.
On one particular scanning day, a patient had to be cancelled 
because of problems with venous access, a rare occurrence. There 
is a fi nite time slot within the working day for patients to have venous 
access organised and any delay has a ‘knock on’ effect with the 
timings for other patients. Because the FDG-18 solution has a relatively 
short physical half-life, a decision was made to cancel the patient, 
following numerous attempts by a range of skilled professionals and 
even an anaesthetist. This decision was a diffi cult one to make and 
the fact that two patients had fl own from Scotland to have their scan 
at the site had an infl uencing factor. Decision-making formulates an 
important aspect of a practitioner who may work within an advanced 
area of nuclear medicine such as PET/CT6, but it is important to adhere 
to policies within any NHS Trust.  
As much of the procedure as possible has to be explained to the 
patient before the injection of FDG-18, because the radiation dose 
received by the practitioner is directly proportional to the time spent 
with the patient, the distance from the source of radiation and the 
degree of secondary shielding that exists. Strict adherence to the 
ARSAC3 limits is paramount. The maximum dose limit for a half-body 
PET/CT scan (which typically includes orbits to upper femora) is 400 
MBq3. This value may be increased if the patient’s weight is in excess 
of 100kg, but this is at the discretion of the clinical site’s ARSAC 
licence holder. 
Measurement of the FDG-18 radioisotope is undertaken by the 
practitioner, who is also responsible for the administration and post 
assay recording of the ‘empty’ vial. Documentation of the values 
and times is crucial, because the calculation of standard uptake 
values (SUVs) cannot be accurately undertaken otherwise. Reporting 
radiologists may wish to assess SUVs in patients who have undergone 
chemotherapy treatment and are reviewing the tumour uptake 
of FDG-18.  
The preparation of consumables, sharps bins, patient documentation, 
patient dose calculation sheets and overall documentation/record 
keeping is paramount to the overall fl uid running of a PET/CT service. 
In addition, obtaining the patient’s height and weight is crucial to the 
calculation of SUVs within the scan, along with the pre- and post-
injection dose values and times. All this was vital fi rst hand experience 
in drawing up, measuring, safely injecting and disposing of FDG-18. 
A three-way tap is an essential piece of kit in terms of being able 
to ‘fl ush’ the FDG-18 (contained in a vial, encased in a tungsten/lead 
NEXT MONTH: Marc recounts the clinical experiences of 
his placement.
case) with a suffi cient amount of saline fl uid. All syringes are leur-lock 
design to prevent any accidental spillage of the radioactive solution. 
A 3ml syringe is also used to draw off a sample of blood from the 
patient, prior to the administration of the FDG-18 solution, in order to 
measure the blood sugar level (BSL). A high BSL (greater than 
10mmol/L) constitutes the potential for a poor scan, in terms of image 
quality, because the patient’s body already possesses suffi cient 
amounts of glucose, which then prevents the maximum uptake of 
FDG-18 within the patient’s cells. This scenario may affect the overall 
sensitivity of a PET/CT scan.  
Cold winter days may also potentially cause image quality 
problems. Cold patients may shiver and cause false uptake to occur 
within their spinous processes and various muscle groups within their 
bodies. So it is crucial that patients are kept as warm as possible, 
through blankets and an on-board heating system, as soon as they 
come on board the scanner. In addition, a lot of patients fail to drink 
any water prior to their attendance, which also affected overall scan 
quality. 
Personal dosimetry
All PET/CT practitioners are issued with electronic personal dosimeters 
(EPDs), which provide an instantaneous readout of a cumulative 
dose received during a working day. It is important that the classifi ed 
annual radiation dose of 6mSv7 is not exceeded, which can constitute 
additional health checks and a scoping exercise being conducted. 
Roberts8 and Benatar et al9 identifi ed the increased dose from PET/CT 
examinations compared to conventional nuclear medicine procedures 
for clinical practitioners and the use of an EPD unit is considered 
crucial in order to monitor personal dose limits. 
Strict adherence to clinical protocols and audit monitoring of 
staff ensure that all PET/CT practitioners within AML are not classifi ed 
workers. 
In addition to the personal EPD, a fi nger thermoluminescent 
dosimeter (TLD) and a body TLD are also worn by PET/CT practitioners 
and replaced on a monthly basis. Handling the tungsten/lead 
composite syringe shields took some practice and I was fortunate 
enough to receive excellent hands-on training from the staff I worked 
with. Trying to draw up 0.6ml of FDG-18 with a 25G butterfl y in a 
fragile vein of a chemotherapy patient in a confi ned space, with the 
knowledge of the associated decay factor requires skill, confi dence 
and competence.  
A colleague once told me that “you don’t fi nd PET/CT, it fi nds 
you…”  This reminded me of the development required within all 
areas of medical imaging and the necessity to always engage with 
change, professionalism and competency.
